ALK and non-small cell lung carcinoma: As a result, we conducted a retrospective population-based cohort study using Ontario’s health administrative database to examine the real-world clinical outcomes of patients with advanced ALK-positive NSCLC receiving ALK TKIs in Ontario, Canada.